Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21880477 | 0.78 | HTR2A (0.44) | HTR2AHTR2CHTR2BALDH1A1HSD17B10 | |
| SCHEMBL20155649 | 0.77 | HTR2A (0.41) | HTR2AHTR2CHTR2BPDE10AALDH1A1 | |
| SCHEMBL24380267 | 0.74 | CYP1A2 (0.39) | HTR2AHTR2CHTR2BPDE10AALDH1A1 | |
| SCHEMBL23841158 | 0.74 | HTR2A (0.38) | HTR2AHTR2CHTR2BPDE10AALDH1A1 | |
| SCHEMBL19117590 | 0.74 | HTR2A (0.47) | HTR2AHTR2CHTR2B | |
| SCHEMBL21250494 | 0.71 | TRPV1 (0.36) | HTR2AHTR2CHTR2BPDE10AALDH1A1 | |
| SCHEMBL19954911 | 0.70 | HTR2A (0.38) | HTR2AHTR2CHTR2BALDH1A1HSD17B10 | |
| SCHEMBL19733400 | 0.69 | RAB9A (0.46) | ALDH1A1HSD17B10CYP1A2ESR2 | |
| SCHEMBL2607435 | 0.69 | ADRA2A (0.44) | ALDH1A1CYP1A2 | |
| SCHEMBL29875062 | 0.69 | ADRA2A (0.44) | ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411419-A1 | SMALL MOLECULE MODULATORS OF MHC-I | RETROVIROX, INC. | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411419-A1 | SMALL MOLECULE MODULATORS OF MHC-I | CD74, HLA-DRB1, MICA | HTR2A 771/4885HTR2C 879/4885HTR2B 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.